Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has expanded its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ) to help expedite discovery and development efforts.
Subscribe to our email newsletter
With this expansion, Pfizer has leased the complete 500,000ft² at 610 Main Street in Kendall Square and this space will continue to house the research and development (R&D) activities that relocated to 610 Main Street in 2014.
The space will allow the consolidation of Pfizer’s three other leased spaces in Cambridge into the one campus.
The company noted that the most recent lease addition secures an added 130,000ft² of space for potential expansion in the future and will be available for sub-tenancy in 2017.
Pfizer Cambridge head Michael Ehlers said: "We are creating an expansive research facility that will allow for stronger collaborations in the Boston/Cambridge bioscience community and open new doors to unique partnerships.
"As researchers, we work every day to advance the science that creates new transformative medicines for patients in need.
"By bringing together some of the greatest minds in the industry in an open and flexible environment, we believe we will be poised now more than ever to help accelerate discovery, incubate innovation in creative ways, and increase the pace of innovation."
Following consolidation of the three remote sites, 610 Main Street will house about 1,000 Pfizer employees.
The company’s R&D efforts in Cambridge will continue to focus on rare diseases, cardiovascular and metabolic disease, inflammation and immunology, neuroscience, and advanced biotherapeutic technologies.